Corcept Phase 2 Study of Dazucorilant Demonstrates Two-Year Overall Survival Benefit in Patients with Amyotrophic Lateral Sclerosis
businesswire.com
⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in